journal article·2024-06Open access

Spiky metal-organic framework nanosystem for enhanced cuproptosis-mediated cancer immunotherapy

Manman Xu, Hengwen Chen, Guanghui Zhu, Xiaoyu Zhu, Ruike Gao, Bowen Xu, Xiaotong Song, Xinpu Han, Tianyu Shao, Qianhui Sun, Zhigang Xiao, Heping Wang, Ying Zhang, Ge Yang, Jie Li

Nano Today· Volume 56

Abstract

Immunotherapy, particularly αPD-1 therapy, has been hailed as a significant breakthrough in cancer treatment. However, the limited response rates and unknown mechanisms hinder the clinical application of αPD-1 blockade boosting with hybrid nanoparticles. Herein, we introduce a strategy to enhance cancer immunotherapy by leveraging cuproptosis, initiated by the spiky copper-based metal-organic framework (S@Cu-MOF) loaded with polyphyllin I (PPI) and synergized with αPD-1 therapy. Interestingly, the unique spiky structure of S@Cu-MOF not only significantly enhances tumor cell uptake but also leads to pronounced DNA damage. The application of S@Cu-MOF/PPI with αPD-1 therapy led to obvious tumor regression and prolonged survival due to cuproptosis, which involved substantial mitochondrial damage. This process amplifies the cGAS/STING immune pathway, enhancing the immune response against cancer. Additionally, this strategy promoted immunogenic cell death (ICD), recruitment of mature dendritic cells (DCs), T cell-mediated immunity, and effective memory CD8+ T cells, resulting in significant abscopal tumor suppression and lung metastasis reduction. Our study highlights the potential of S@Cu-MOF/PPI as a sensitizer for αPD-1 with the mechanism of cuproptosis and the cGAS/STING pathway, offering a promising strategy for the next generation of immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (55)

Show source-provided references
1. Liu · Signal Transduct. Target Ther. · 2023 · 8 · 10410.1038/s41392-023-01365-z ↗
2. Fusco · JAMA Oncol. · 2021 · 710.1001/jamaoncol.2020.6371 ↗
3. Chu · Mol. Cancer · 2023 · 22 · 1
4. Lu · Innovation · 2020 · 1
5. Gong · J. Immunother. Cancer · 2018 · 6 · 1
6. Tisato · Med. Res. Rev. · 2010 · 30 · 70810.1002/med.20174 ↗
7. Guan · Biomed. Pharmacother. · 2023 · 16310.1016/j.biopha.2023.114791 ↗
8. Ji · Free Radic. Biol. Med. · 2018 · 129 · 21510.1016/j.freeradbiomed.2018.09.017 ↗
9. Chen · Signal Transduct. Target Ther. · 2022 · 7 · 37810.1038/s41392-022-01229-y ↗
10. Kim · Exp. Mol. Med. · 2023 · 55 · 51010.1038/s12276-023-00965-7 ↗
11. Cai · Chem. Sci. · 2023 · 14 · 437510.1039/D2SC06036A ↗
12. Yang · J. Oncol. · 2023 · 2023 · 2733232
13. Huang · Sci. Rep. · 2022 · 12 · 2138610.1038/s41598-022-25998-2 ↗
14. Chai · Chem. Biodivers. · 2018 · 1510.1002/cbdv.201800314 ↗
15. Zhang · PLoS One · 2016 · 11
16. Liu · Acta Biochim. Biophys. Sin. · 2017 · 49 · 47910.1093/abbs/gmx033 ↗
17. Xu · ACS Appl. Mater. Interfaces · 2023 · 15 · 1747010.1021/acsami.2c21005 ↗
18. Liu · J. Control Release · 2020 · 328 · 110.1016/j.jconrel.2020.08.015 ↗
19. Furukawa · Science · 2013 · 34110.1126/science.1230444 ↗
20. Cun · Adv. Colloid Interface Sci. · 2022
21. Ding · Adv. Drug Deliv. Rev. · 2022
22. Wang · J. Sci. Adv. Mater. Dev. · 2023 · 8
23. Johnson · Nat. Nanotechnol. · 2018 · 13 · 98010.1038/s41565-018-0292-y ↗
24. Chen · Adv. Funct. Mater. · 2020 · 30
25. Ren · Int. J. Biol. Macromol. · 2021 · 191 · 109610.1016/j.ijbiomac.2021.09.184 ↗
26. Fu · Front. Bioeng. Biotechnol. · 2022 · 10
27. Zheng · J. Mater. Chem. B · 2016 · 4 · 124710.1039/C5TB02624E ↗
28. Guo · ACS Nano · 2023 · 17 · 1079210.1021/acsnano.3c02287 ↗
29. Villaseñor · Nat. Biotechnol. · 2020 · 38 · 72810.1038/s41587-020-0434-2 ↗
30. Pan · J. Control Release · 2023 · 357 · 13310.1016/j.jconrel.2023.03.041 ↗
31. Szabo · Annu Rev. Biophys. · 2023 · 52 · 22910.1146/annurev-biophys-092622-094853 ↗
32. Jin · Materials · 2023 · 68 · 108
33. Lin · ACS Appl. Mater. Interfaces · 2021 · 13 · 5069510.1021/acsami.1c13517 ↗
34. Wang · J. Nanobiotechnol. · 2022 · 20 · 7810.1186/s12951-022-01275-2 ↗
35. Bai · Adv. Sci. · 2021 · 8 · 210265810.1002/advs.202102658 ↗
36. Ahmad · Oncol. Targ. Ther. · 2021 · 182110.2147/OTT.S287354 ↗
37. Zhang · Nat. Commun. · 2022 · 13 · 494810.1038/s41467-022-32645-x ↗
38. Wartewig · Trends Immunol. · 2019 · 40 · 40310.1016/j.it.2019.03.005 ↗
39. Xie · Mol. Cancer · 2023 · 22 · 4610.1186/s12943-023-01732-y ↗
40. Fu · Toxicol. Mech. Methods · 2020 · 30 · 16710.1080/15376516.2019.1701594 ↗
41. Guo · Adv. Mater. · 2023 · 35 · 221226710.1002/adma.202212267 ↗
42. Huang · Bioact. Mater. · 2023 · 21 · 381
43. Zhang · Nat. Commun. · 2019 · 10 · 170410.1038/s41467-019-09566-3 ↗
44. Yang · Phytomedicine · 2024 · 122
45. Tsvetkov · Science · 2022 · 375 · 125410.1126/science.abf0529 ↗
46. Garza · Trends Endocrinol. Metab. · 2022 · 34 · 2110.1016/j.tem.2022.11.001 ↗
47. Zhao · Theranostics · 2021 · 11 · 184510.7150/thno.50905 ↗
48. Guo · Trends Pharmacol. Sci. · 2022 · 43 · 95710.1016/j.tips.2022.08.006 ↗
49. Xu · Adv. Funct. Mater. · 2022 · 32
50. Liu · J. Nanobiotechnol. · 2020 · 18 · 1
51. Wculek · Nat. Rev. Immunol. · 2020 · 20 · 710.1038/s41577-019-0210-z ↗
52. Galluzzi · Nat. Rev. Immunol. · 2017 · 17 · 9710.1038/nri.2016.107 ↗
53. Zheng · ACS Nano · 2023 · 17 · 997210.1021/acsnano.2c11964 ↗
54. Jin · J. Biomed. Nanotechnol. · 2014 · 10 · 239310.1166/jbn.2014.1898 ↗
55. Mao · Biomaterials · 2019 · 188 · 17310.1016/j.biomaterials.2018.10.012 ↗